Illumina Inc. (NASDAQ:ILMN) was downgraded by stock analysts at Vetr from a “buy” rating to a “hold” rating in a report issued on Monday. They currently have a $187.86 price target on the life sciences company’s stock. Vetr‘s price objective points to a potential upside of 1.63% from the company’s current price.

A number of other analysts have also commented on ILMN. Zacks Investment Research raised Illumina from a “sell” rating to a “hold” rating in a research report on Monday, July 4th. Cantor Fitzgerald reaffirmed a “hold” rating on shares of Illumina in a research report on Wednesday, June 29th. Mizuho boosted their target price on Illumina from $138.00 to $148.00 and gave the company a “neutral” rating in a research report on Wednesday, July 27th. Canaccord Genuity set a $165.00 target price on Illumina and gave the company a “hold” rating in a research report on Friday. Finally, Citigroup Inc. boosted their target price on Illumina from $175.00 to $190.00 and gave the company a “buy” rating in a research report on Monday, September 12th. One research analyst has rated the stock with a sell rating, sixteen have given a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $165.56.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Shares of Illumina (NASDAQ:ILMN) traded up 0.20% during midday trading on Monday, hitting $184.85. The company’s stock had a trading volume of 1,889,978 shares. The company has a 50-day moving average price of $175.01 and a 200 day moving average price of $156.56. Illumina has a 1-year low of $127.10 and a 1-year high of $196.47. The company has a market cap of $27.10 billion, a P/E ratio of 63.30 and a beta of 0.47.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.13. Illumina had a return on equity of 23.69% and a net margin of 18.73%. The firm earned $600 million during the quarter, compared to analyst estimates of $31.91 million. During the same period last year, the company posted $0.80 EPS. The business’s quarterly revenue was up 11.3% on a year-over-year basis. On average, equities research analysts predict that Illumina will post $3.53 EPS for the current year.

In related news, Director Robert S. Epstein sold 300 shares of the stock in a transaction on Tuesday, September 20th. The stock was sold at an average price of $174.29, for a total value of $52,287.00. Following the transaction, the director now owns 6,924 shares of the company’s stock, valued at $1,206,783.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jay T. Flatley sold 20,000 shares of the stock in a transaction on Tuesday, August 23rd. The shares were sold at an average price of $172.99, for a total value of $3,459,800.00. Following the completion of the transaction, the director now directly owns 508,061 shares in the company, valued at approximately $87,889,472.39. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Physicians Financial Services Inc. raised its stake in Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock valued at $103,000 after buying an additional 700 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in Illumina by 25.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 789 shares of the life sciences company’s stock valued at $110,000 after buying an additional 158 shares during the last quarter. Fuller & Thaler Asset Management Inc. acquired a new stake in Illumina during the second quarter valued at about $112,000. Ropes Wealth Advisors LLC raised its stake in Illumina by 72.6% in the second quarter. Ropes Wealth Advisors LLC now owns 863 shares of the life sciences company’s stock valued at $121,000 after buying an additional 363 shares during the last quarter. Finally, Checchi Capital Advisers LLC raised its stake in Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock valued at $134,000 after buying an additional 22 shares during the last quarter. 95.22% of the stock is currently owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

5 Day Chart for NASDAQ:ILMN

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.